Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790184 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
Compared to EORTC risk stratification, the EAU categories reclassifies 37.9% patients into a higher risk group of recurrence and 11.8% into a higher risk of progression. However, the novel risk stratification assigns most patients to the same treatment as the more complex EORTC tables and can be regarded as an alternative tool for treatment decision-making.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Malte M.D., Shahrokh F. M.D., Luis M.D., Joseph J. M.D., Mohammad M.D., Beat M.D., Andrea M.D., Dafina Ph.D., Pierre I. M.D., Marek M.D., Mithat M.D., Evanguelos M.D.,